yahoo.comSEP 223 min read$TRLV

2 Cannabis Stocks That Are Quietly Trouncing the Market in 2026

Trulieve Cannabis (TRLV) and Cronos Group (CRON) have outperformed the S&P 500 in 2026, with both stocks up 27% through Sept. 18. Trulieve reported Q2 revenue of $271M, EBITDA of $98M, and $74M in free cash flow, while Cronos saw Q2 revenue rise 58% to $53M. Both companies face regulatory risks but have shown strong financial performance.

Original reporting

yahoo.com

Published Sep 22, 2026, 10:30 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 22, 2026, 11:25 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

2 Cannabis Stocks That Are Quietly Trouncing the Market in 2026 — source image — Source · yahoo.com

Decision brief

The 30-second read

$TRLVBullishLow

Why it matters

Both firms display stronger fundamentals than typical peers, suggesting possible sector rotation.

Market read

The strong cash positions and revenue growth may influence investor sentiment toward cannabis equities.

What to watch

Regulatory risks and potential price pressure in key markets could limit upside.

Relevance 4/10Novelty 2/10Timing: as of Sep 2026

Background

The article reviews recent financial performance of two publicly traded cannabis companies, noting cash generation and revenue growth.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TRLVBullishMedium confidence

Context

Q2 revenue $271M, $74M free cash flow and $325M cash balance disclosed for 2026.

Expected impact

Potential upside if cash is deployed for growth or dividends.

Evidence & confidence

Quarterly cash flow figures are solid for a cannabis firm, indicating financial stability.

$CRONBullishMedium confidence

Context

Q2 net revenue $53M (+58% YoY) and $827M cash position reported for 2026.

Expected impact

Likely support for the stock given strong balance sheet.

Evidence & confidence

Large cash reserves and rapid revenue growth are uncommon in the sector.

Market effects

Sector

Highlights improving fundamentals in the cannabis sector, may lift peer valuations.

Regional

U.S. and Canadian cannabis firms could see increased investor interest.

Global

Shows potential for broader acceptance of cannabis stocks internationally.

Counterpoint

What could challenge this read

Valuations may already price in growth; cash may not translate to earnings without regulatory clarity.

Key entities

company
Trulieve Cannabis
U.S. cannabis producer listed on NYSE (TRLV).
company
Cronos Group
Canadian cannabis company listed on NASDAQ (CRON).

Read at source ← All news

SEP 30

$TRLVHigh

Why is Trulieve Cannabis stock sliding today?

Trulieve Cannabis (TRLV) shares fell 6.5% in pre-market trading after announcing a licensing deal with Connected Cannabis, which investors reassessed for costs and risks. CEO Kim Rivers' share sale plan and institutional rebalancing added pressure. Q2 revenue was $271M, down 10% YoY, with a net loss. Broader market conditions offered no support.

investing.com1 min

SEP 29

$MSOSHigh

MSOS, TRLV Slide After Hours As DEA Judge Pauses Cannabis Rescheduling Case

MSOS, an ETF, and TRLV, one of its holdings, fell about 8-9% after hours as a federal judge paused a cannabis rescheduling case. The delay impacts investors' expectations for near-term changes to marijuana's legal status, which could affect the industry.

stocktwits.com2 min

AUG 29

$TRLVMed

Trulieve Cannabis (TRLV) Is Up 6.5% After ESOP-Linked US$55.5 Million Share Issuance - Has The Bull Case Changed?

Trulieve Cannabis (TRLV) issued 10 million shares worth $55.5 million in an ESOP-related offering, causing a 6.5% stock price increase. The company also authorized a $50 million share buyback program. Analysts project varying revenue and earnings forecasts for 2029, with some seeing significant upside and others a more pessimistic outlook. Q2 2026 sales declined year over year, and net loss widened, keeping margin trends and capital deployment in focus.

simplywall.st3 min

AUG 29

$ZIMMedAI 8/10

Dow, S&P 500, Nasdaq Futures Rise On AI, Fed Watch After Holiday Break: Why ZIM, AAPL, TCNNF, DIS Kept Traders On Edge Today

U.S. stock futures rose late Monday, with Nasdaq up 0.01%, S&P 500 up 0.1%, and Dow up 0.05%. Investors focused on AI disruption, Fed rate path, and inflation data. ZIM agreed to a $4.2B acquisition by Hapag-Lloyd at $35 per share. AAPL announced a March 4 event, potentially featuring new products. TCNNF and DIS also drew attention.

stocktwits.com2 min

AUG 10

$TRLVMedAI 8/10

Trulieve Cannabis Q2 Earnings Call Highlights

Trulieve Cannabis reported Q2 revenue of $271 million, including $222 million medical-only revenue. Adjusted EBITDA was $98 million (36% margin). Operating cash flow was $53 million and free cash flow $32 million, with $325 million cash and $289 million debt. The company authorized a $50 million share repurchase program in June. It expects Q3 medical-only revenue comparable to $222 million and raised capex to $95 million.

yahoo.com7 min

AUG 7